Hospital
Mainehealth
Mainehealth was paid $5.06M by Medicaid between Jan 2018 and Dec 2024, across 309 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoMAINEHEALTH
NORWAY, ME 04268
NORWAY, ME 04268
33aNPI1346299815assigned 05/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.06M
24GClaims707,876
24DCodes billed309
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#15 of 33
Median peer was paid$4.34M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HUNTER, ROBERT controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,109 | $706K | |
| 2019 | 84,463 | $757K | |
| 2020 | 81,195 | $601K | |
| 2021 | 106,687 | $645K | |
| 2022 | 113,083 | $755K | |
| 2023 | 120,552 | $798K | |
| 2024incomplete | 123,787 | $794K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 37,485 | 23,666 | $517K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.9% | 3,834 | 3,617 | $402K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 13,059 | 7,864 | $299K |
| G0378 | Hospital observation service, per hour | 4.9% | 1,698 | 1,459 | $247K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.4% | 24,838 | 18,488 | $221K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 3,055 | 2,879 | $200K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.6% | 2,065 | 1,245 | $180K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 19,858 | 6,547 | $166K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.1% | 4,042 | 3,501 | $158K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 13,585 | 11,926 | $157K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 19,559 | 13,915 | $153K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 1,333 | 1,287 | $152K |
297 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 4,520 | $141K |
| 71046 | Radiologic examination, chest; 2 views | 2.8% | 7,016 | $140K |
| A0427 | Emergency ambulance ride, advanced life support | 2.3% | 2,669 | $115K |
| 71250 | 2.0% | 1,204 | $103K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 7,026 | $103K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.9% | 1,094 | $96K |
| 80053 | Comprehensive metabolic panel | 1.6% | 32,896 | $82K |
| A0425 | Ground mileage, per statute mile | 1.5% | 8,940 | $75K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 9,866 | $70K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 4,055 | $54K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 8,857 | $54K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 5,508 | $54K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 346 | $48K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,647 | $45K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,463 | $42K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,515 | $40K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,035 | $40K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,280 | $39K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,331 | $39K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,815 | $35K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,432 | $33K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,318 | $32K |
| 73562 | <1% | 1,473 | $28K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,079 | $28K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,983 | $23K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 502 | $22K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 756 | $21K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,284 | $21K |
| 97161 | <1% | 2,124 | $20K | |
| 73502 | <1% | 720 | $19K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 690 | $19K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,545 | $18K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 246 | $18K |
| 73630 | <1% | 1,294 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 52,679 | $17K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 7,484 | $17K |
| 73030 | <1% | 880 | $16K | |
| 97162 | <1% | 1,385 | $15K | |
| 94060 | <1% | 346 | $13K | |
| 82607 | <1% | 2,971 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,389 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,114 | $12K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 529 | $11K |
| 93971 | <1% | 204 | $10K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 114 | $10K |
| 72100 | <1% | 400 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 743 | $9K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,491 | $9K |
| 84484 | <1% | 7,482 | $9K | |
| 73610 | <1% | 977 | $9K | |
| 85610 | <1% | 7,106 | $8K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 12,780 | $7K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 239 | $7K |
| 81001 | <1% | 9,661 | $7K | |
| 93017 | <1% | 160 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,538 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,405 | $7K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 15 | $7K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,774 | $6K |
| 82728 | <1% | 2,798 | $6K | |
| 83550 | <1% | 2,054 | $6K | |
| 76642 | <1% | 357 | $6K | |
| 83735 | <1% | 6,215 | $6K | |
| 86140 | <1% | 3,982 | $5K | |
| 93242 | <1% | 250 | $5K | |
| 83880 | <1% | 3,018 | $5K | |
| 83540 | <1% | 2,187 | $5K | |
| 76770 | <1% | 53 | $5K | |
| 96376 | <1% | 1,583 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 559 | $4K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,439 | $4K |
| 85027 | <1% | 3,991 | $4K | |
| 82746 | <1% | 1,042 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13,152 | $4K |
| 87186 | <1% | 3,040 | $4K | |
| 74018 | <1% | 620 | $4K | |
| 73110 | <1% | 515 | $4K | |
| 73130 | <1% | 397 | $4K | |
| 80061 | Lipid panel | <1% | 10,578 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 756 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,701 | $3K |
| 87077 | <1% | 3,522 | $3K | |
| V2632 | Posterior chamber intraocular lens | <1% | 15 | $3K |
| 85652 | <1% | 3,329 | $3K | |
| 83605 | <1% | 2,684 | $3K | |
| 81003 | <1% | 4,899 | $3K | |
| 83690 | <1% | 5,574 | $3K | |
| 20610 | <1% | 312 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,343 | $3K |
| 84439 | <1% | 2,099 | $2K | |
| 94729 | <1% | 181 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 24 | $2K |
| 86850 | <1% | 2,313 | $2K | |
| 84156 | <1% | 495 | $2K | |
| 80076 | <1% | 1,918 | $2K | |
| 87040 | <1% | 1,800 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,039 | $2K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 829 | $2K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,632 | $2K |
| 76536 | <1% | 67 | $2K | |
| 93356 | <1% | 263 | $2K | |
| 82784 | <1% | 377 | $2K | |
| 86618 | <1% | 1,149 | $2K | |
| 90715 | <1% | 429 | $2K | |
| 70498 | <1% | 40 | $2K | |
| 86803 | <1% | 2,541 | $2K | |
| 70496 | <1% | 40 | $2K | |
| 87070 | <1% | 4,475 | $2K | |
| 84100 | <1% | 851 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 282 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,316 | $1K |
| 94726 | <1% | 126 | $1K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 139 | $1K |
| 80069 | <1% | 64 | $1K | |
| 36591 | <1% | 162 | $1K | |
| 84460 | <1% | 425 | $1K | |
| 99219 | <1% | 226 | $1K | |
| 86900 | <1% | 2,330 | $1K | |
| 82570 | <1% | 1,655 | $1K | |
| 86901 | <1% | 2,344 | $988.63 | |
| 51798 | <1% | 250 | $948.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,671 | $945.15 |
| 82043 | <1% | 394 | $936.36 | |
| 85730 | <1% | 1,503 | $906.61 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 587 | $890.41 |
| 83970 | <1% | 256 | $888.94 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,754 | $883.24 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 885 | $880.70 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,655 | $880.57 |
| 77065 | Tomosynthesis, mammo | <1% | 72 | $857.27 |
| 84703 | <1% | 3,419 | $821.10 | |
| 85379 | <1% | 657 | $780.34 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 516 | $744.79 |
| 97165 | <1% | 97 | $722.40 | |
| 82948 | <1% | 6,469 | $687.51 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 442 | $679.21 |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 42 | $669.48 |
| 76376 | <1% | 25 | $662.72 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 296 | $660.24 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,438 | $616.16 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,776 | $612.02 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 544 | $602.09 |
| 87205 | <1% | 1,491 | $592.33 | |
| 80306 | <1% | 1,435 | $591.93 | |
| 86706 | <1% | 326 | $591.35 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 390 | $589.88 |
| 99217 | <1% | 265 | $582.69 | |
| 82803 | <1% | 296 | $574.43 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,627 | $562.19 |
| 85018 | <1% | 2,123 | $547.57 | |
| 97116 | <1% | 109 | $534.53 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 537 | $512.39 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,133 | $505.69 |
| 87468 | <1% | 326 | $495.03 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 217 | $493.83 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,282 | $488.89 |
| 87340 | <1% | 1,339 | $482.60 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 139 | $477.16 |
| 87469 | <1% | 326 | $476.19 | |
| 73140 | <1% | 87 | $471.93 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 62 | $450.28 |
| 71271 | <1% | 81 | $448.50 | |
| 87481 | <1% | 1,028 | $434.88 | |
| 96367 | <1% | 42 | $426.66 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,752 | $421.24 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,542 | $413.82 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,352 | $392.33 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,757 | $381.58 |
| 72110 | <1% | 17 | $378.36 | |
| 86704 | <1% | 233 | $378.01 | |
| 97166 | <1% | 74 | $376.07 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,069 | $371.10 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 12 | $358.45 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 163 | $332.98 |
| 93016 | <1% | 186 | $326.19 | |
| J3490 | Unclassified drugs | <1% | 57 | $325.95 |
| 59025 | Fetal non-stress test | <1% | 1,874 | $321.75 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,544 | $317.38 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 167 | $313.93 |
| 99220 | <1% | 41 | $308.45 | |
| 88142 | <1% | 1,323 | $308.36 | |
| 84702 | <1% | 730 | $305.92 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,750 | $301.31 |
| 73080 | <1% | 53 | $295.45 | |
| 81002 | <1% | 2,632 | $280.97 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 100 | $271.77 |
| 00812 | <1% | 81 | $260.11 | |
| 87522 | Neg quan hep c or qual rna | <1% | 94 | $245.85 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 46 | $233.88 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 552 | $217.65 |
| 87511 | <1% | 522 | $217.44 | |
| 93018 | <1% | 186 | $217.40 | |
| 82550 | <1% | 218 | $214.63 | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 13 | $208.21 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 317 | $207.16 |
| 92557 | <1% | 141 | $203.18 | |
| 92567 | <1% | 250 | $199.77 | |
| 72070 | <1% | 12 | $186.56 | |
| 97035 | <1% | 121 | $186.45 | |
| 80305 | <1% | 5,861 | $184.90 | |
| 99459 | <1% | 259 | $182.59 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 279 | $179.69 |
| 96415 | <1% | 16 | $173.82 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 70 | $170.30 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 160 | $157.09 |
| 84550 | <1% | 85 | $141.89 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 109 | $118.25 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 99 | $114.91 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 414 | $114.01 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 226 | $113.41 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 949 | $110.29 |
| 99223 | Prolong inpt eval add15 m | <1% | 41 | $108.67 |
| 81025 | <1% | 3,080 | $106.95 | |
| 84450 | <1% | 71 | $104.98 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 184 | $104.61 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 355 | $98.28 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 129 | $90.46 |
| 83615 | <1% | 31 | $83.58 | |
| 82044 | <1% | 716 | $82.95 | |
| 93244 | <1% | 106 | $81.01 | |
| 12001 | <1% | 78 | $80.75 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,227 | $74.26 |
| 87400 | <1% | 290 | $69.20 | |
| 97014 | <1% | 22 | $69.19 | |
| 00811 | <1% | 30 | $68.04 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 330 | $66.57 |
| 87210 | <1% | 2,068 | $63.54 | |
| 82565 | <1% | 64 | $62.29 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,435 | $61.08 |
| 10060 | <1% | 23 | $51.98 | |
| 82375 | <1% | 58 | $50.86 | |
| 86780 | <1% | 1,376 | $49.61 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 60 | $48.64 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 29 | $48.36 |
| 84403 | <1% | 29 | $48.15 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 64 | $44.29 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 464 | $43.70 |
| 87493 | <1% | 25 | $40.17 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 334 | $39.94 |
| G0008 | Administration of influenza virus vaccine | <1% | 270 | $33.35 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 42 | $33.05 |
| 87634 | <1% | 53 | $31.37 | |
| 84165 | <1% | 16 | $29.27 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 444 | $28.21 |
| 83721 | <1% | 39 | $27.22 | |
| 80164 | <1% | 27 | $24.45 | |
| 80050 | General health panel | <1% | 59 | $21.54 |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $20.77 |
| 86038 | <1% | 28 | $19.80 | |
| 87420 | <1% | 186 | $17.10 | |
| 86762 | <1% | 331 | $12.69 | |
| 82105 | <1% | 61 | $12.03 | |
| 86708 | <1% | 61 | $11.81 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 29 | $9.40 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 71 | $9.34 |
| 86364 | <1% | 92 | $8.90 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 27 | $7.44 |
| 83655 | <1% | 1,193 | $4.20 | |
| 87081 | <1% | 24 | $3.86 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 22 | $3.27 |
| 85007 | <1% | 29 | $2.91 | |
| 90686 | <1% | 168 | $2.38 | |
| 82947 | <1% | 51 | $0.37 | |
| 0004A | <1% | 166 | $0.29 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 328 | $0.26 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 64 | $0.10 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,080 | $0.09 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 246 | $0.01 |
| 91300 | 0% | 516 | $0.00 | |
| 77080 | 0% | 27 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 50 | $0.00 |
| 0071A | 0% | 173 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 41 | $0.00 |
| 0002A | 0% | 210 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 36 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| 83516 | 0% | 43 | $0.00 | |
| 76819 | Fetal biophysical profile; without non-stress testing | 0% | 242 | $0.00 |
| 0064A | 0% | 572 | $0.00 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 0% | 127 | $0.00 |
| 90834 | Psychotherapy session, about 45 minutes | 0% | 529 | $0.00 |
| 80178 | 0% | 14 | $0.00 | |
| 0072A | 0% | 132 | $0.00 | |
| 58300 | 0% | 27 | $0.00 | |
| 82950 | 0% | 346 | $0.00 | |
| 0001A | 0% | 150 | $0.00 | |
| 0012A | 0% | 1,411 | $0.00 | |
| 91301 | 0% | 1,192 | $0.00 | |
| 36416 | 0% | 87 | $0.00 | |
| 90656 | 0% | 15 | $0.00 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 60 | $0.00 |
| 0134A | 0% | 51 | $0.00 | |
| 0011A | 0% | 1,423 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 52 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 49 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 12 | $0.00 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUNTER, ROBERT (SENIOR VICE PRESIDENT - FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Mainehealth | Rockport, ME | $31.54M |
| Mainehealth | Farmington, ME | $16.71M |
| Mainehealth | Norway, ME | $10.00M |
| Mainehealth | Norway, ME | $9.84M |
| Mainehealth | Damariscotta, ME | $9.60M |
| Mainehealth | Belfast, ME | $5.33M |
| Mainehealth | Livermore Falls, ME | $3.15M |
| Mainehealth | Boothbay Harbor, ME | $2.90M |
| Mainehealth | Damariscotta, ME | $2.62M |
| Mainehealth | Farmington, ME | $2.36M |
| University Pathologists | Houston, TX | $1.35M |
| Mainehealth | Farmington, ME | $435K |
| P R Hematology Oncology Group INC | Bayamon, PR | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.